Skip to content

Study · Randomized controlled trial · n = 58 · 2017

4 results

Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.

Østergren PB, Kistorp C, Fode M, Henderson J, Bennedbæk FN, Faber J, Sønksen J

The Journal of urology9 Dec 2016Cited by 27 (Europe PMC)

PMID27939836 (opens in a new tab)PMCIDPMC5433917 (opens in a new tab)DOI10.1016/j.juro.2016.12.003 (opens in a new tab)PepBankPUB-27939836
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with advanced prostate cancer, triptorelin produced 29% lower testosterone levels than subcapsular orchiectomy.

    In plain wordsIn men with advanced prostate cancer, triptorelin lowered testosterone more than subcapsular orchiectomy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSerum testosterone
    Study

    n = 58

    Comparator
    Subcapsular orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg as 24-week depot injections · 48 weeksAs given in this study (human).

    Measurements

    Relative testosterone reduction
    29%
    versus subcapsular orchiectomy
    95% CI of relative testosterone reduction
    17.2 to 41.7%
    versus subcapsular orchiectomy

    Source sentences

    Summary
    Triptorelin injections resulted in 29% lower testosterone levels (95% CI 17.2-41.7) compared to subcapsular orchiectomy (p <0.001).
    2 context sentences
    Summary · context
    In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015.
    Summary · context
    Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, more triptorelin recipients reached testosterone below 20 ng/dl at 12 weeks than orchiectomy recipients.

    In plain wordsIn men with prostate cancer, more triptorelin recipients reached low testosterone at 12 weeks than orchiectomy recipients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTestosterone below 20 ng/dl at 12 weeks
    Study

    n = 58

    Comparator
    Subcapsular orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg as 24-week depot injections · 48 weeksAs given in this study (human).

    Measurements

    Responder proportion
    97%
    triptorelin at 12 weeks
    Responder proportion
    79%
    orchiectomy at 12 weeks

    Source sentences

    Summary
    A significantly higher proportion of men receiving triptorelin had testosterone levels less than 20 ng/dl at 12 and 48 weeks compared to men undergoing orchiectomy (97% vs 79% and 100% vs 87%, respectively, p <0.05).
    2 context sentences
    Summary · context
    In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015.
    Summary · context
    Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, more triptorelin recipients reached testosterone below 20 ng/dl at 48 weeks than orchiectomy recipients.

    In plain wordsIn men with prostate cancer, more triptorelin recipients reached low testosterone at 48 weeks than orchiectomy recipients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTestosterone below 20 ng/dl at 48 weeks
    Study

    n = 58

    Comparator
    Subcapsular orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg as 24-week depot injections · 48 weeksAs given in this study (human).

    Measurements

    Responder proportion
    100%
    triptorelin at 48 weeks
    Responder proportion
    87%
    orchiectomy at 48 weeks

    Source sentences

    Summary
    A significantly higher proportion of men receiving triptorelin had testosterone levels less than 20 ng/dl at 12 and 48 weeks compared to men undergoing orchiectomy (97% vs 79% and 100% vs 87%, respectively, p <0.05).
    2 context sentences
    Summary · context
    In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015.
    Summary · context
    Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, adrenal androgen reduction did not differ detectably between triptorelin and orchiectomy.

    In plain wordsIn men with prostate cancer, triptorelin and orchiectomy produced similar reductions in adrenal androgens.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeAdrenal androgen reduction
    Study

    n = 58

    Comparator
    Subcapsular orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg as 24-week depot injections · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no detectable difference in the adrenal androgen reduction between the treatment groups.
    2 context sentences
    Summary · context
    In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015.
    Summary · context
    Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.